The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both classes demonstrate remarkable efficacy in promoting glycemic control and facilitating significant weight management, key distinctio… Read More

The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing variations in their… Read More